{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:23:11Z","timestamp":1782807791580,"version":"3.54.5"},"reference-count":68,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cancer Research Institute Lloyd Old STAR Award"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AT011326"],"award-info":[{"award-number":["R01AT011326"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA254104"],"award-info":[{"award-number":["R01CA254104"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA257195"],"award-info":[{"award-number":["R01CA257195"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33CA223947(BDB)"],"award-info":[{"award-number":["R33CA223947(BDB)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA246239"],"award-info":[{"award-number":["R37CA246239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,6,21]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cancer immunotherapies are generally effective in patients whose tumors contain a priori primed T-cells reactive to tumor antigens (TA). One approach to prime TA-reactive T-cells is to administer immunostimulatory molecules, cells, or pathogens directly to the tumor site, that is, in situ vaccination (ISV). We recently described an ISV using Flt3L to expand and recruit dendritic cells (DC), radiotherapy to load DC with TA, and pattern recognition receptor agonists (PRRa) to activate TA-loaded DC. While ISV trials using <jats:italic>synthetic<\/jats:italic> PRRa have yielded systemic tumor regressions, the optimal method to activate DCs is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To discover optimal DC activators and increase access to clinical grade reagents, we assessed whether viral or bacterial components found in common pathogen vaccines are an effective source of <jats:italic>natural PRRa<\/jats:italic> (<jats:italic>naPRRa<\/jats:italic>). Using deep profiling (155-metric) of naPRRa immunomodulatory effects and gene editing of specific PRR, we defined specific signatures and molecular mechanisms by which naPRRa potentiate T-cell priming.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We observed that vaccine naPRRa can be even more potent in activating Flt3L-expanded murine and human DCs than synthetic PRRa, promoting cross-priming of TA-reactive T-cells. We developed a mechanistically diverse naPRRa combination (BCG, PedvaxHIB, Rabies) and noted more potent T-cell cross-priming than with any single naPRRa. The naPRRa triplet\u2014as part of Flt3L-primed ISV\u2014induced greater intratumoral CD8 T-cell infiltration, T-cells reactive to a newly defined tumorous neoantigen, durable tumor regressions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This work provides rationale for the translation of pathogen vaccines as FDA-approved clinical-grade DC activators which could be exploited as immune-stimulants for early phase trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007198","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T12:35:44Z","timestamp":1690202144000},"page":"e007198","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01976585","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03789097","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01976585","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03789097","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03789097","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6113-4182","authenticated-orcid":false,"given":"Mark","family":"Aleynick","sequence":"first","affiliation":[{"name":"Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Svensson-Arvelund","sequence":"additional","affiliation":[{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gvantsa","family":"Pantsulaia","sequence":"additional","affiliation":[{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Kim","sequence":"additional","affiliation":[{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A","family":"Rose","sequence":"additional","affiliation":[{"name":"Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yellin","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics Inc, Hampton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Marsh","sequence":"additional","affiliation":[{"name":"Celldex Therapeutics Inc, Hampton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Oreper","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchit","family":"Jhunjhunwala","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-4094","authenticated-orcid":false,"given":"Christine Carine","family":"Moussion","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D","family":"Brown","sequence":"additional","affiliation":[{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Brody","sequence":"additional","affiliation":[{"name":"Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2025100306261502000_11.7.e007198.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206"},{"key":"2025100306261502000_11.7.e007198.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.007"},{"key":"2025100306261502000_11.7.e007198.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.012"},{"key":"2025100306261502000_11.7.e007198.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"2025100306261502000_11.7.e007198.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5030"},{"key":"2025100306261502000_11.7.e007198.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x"},{"key":"2025100306261502000_11.7.e007198.7","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-0466"},{"key":"2025100306261502000_11.7.e007198.8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/CJI.0000000000000264","article-title":"Racial and socioeconomic disparities in the delivery of Immunotherapy for metastatic Melanoma in the United States","volume":"42","author":"Haque","year":"2019","journal-title":"J Immunother"},{"key":"2025100306261502000_11.7.e007198.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.10.016"},{"key":"2025100306261502000_11.7.e007198.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9793"},{"key":"2025100306261502000_11.7.e007198.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355222"},{"key":"2025100306261502000_11.7.e007198.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.11.066"},{"key":"2025100306261502000_11.7.e007198.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0578"},{"key":"2025100306261502000_11.7.e007198.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.11.005"},{"key":"2025100306261502000_11.7.e007198.15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jamadermatol.2018.1748","article-title":"Combined systemic and Intratumoral administration of human Papillomavirus vaccine to treat multiple cutaneous Basaloid squamous cell Carcinomas","volume":"154","author":"Nichols","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025100306261502000_11.7.e007198.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1904022116"},{"key":"2025100306261502000_11.7.e007198.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251884"},{"key":"2025100306261502000_11.7.e007198.18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG Immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"2025100306261502000_11.7.e007198.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.04.014"},{"key":"2025100306261502000_11.7.e007198.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0257-x"},{"key":"2025100306261502000_11.7.e007198.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.11.6752"},{"key":"2025100306261502000_11.7.e007198.22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1039763","article-title":"Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells","volume":"5","author":"Haabeth","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100306261502000_11.7.e007198.23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.7.3195"},{"key":"2025100306261502000_11.7.e007198.24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502376"},{"key":"2025100306261502000_11.7.e007198.25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1440"},{"key":"2025100306261502000_11.7.e007198.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.05.004"},{"key":"2025100306261502000_11.7.e007198.27","unstructured":"Allen F , Bobanga ID , Rauhe P , et al . Ccl3 augments tumor rejection and enhances Cd8+ T cell infiltration through NK and Cd103+ Dendritic cell recruitment via IFN\u03b3. Oncoimmunology [Internet] 2017. doi:10.1080\/2162402X.2017.1393598 Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/29399390\/?from_single_result=%28%22Oncoimmunology%22%5BJournal%5D%29+AND+%28allen%5BAuthor+-+First%5D%29"},{"key":"2025100306261502000_11.7.e007198.28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101159"},{"key":"2025100306261502000_11.7.e007198.29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101158"},{"key":"2025100306261502000_11.7.e007198.30","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090400"},{"key":"2025100306261502000_11.7.e007198.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0020-5"},{"key":"2025100306261502000_11.7.e007198.32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0391"},{"key":"2025100306261502000_11.7.e007198.33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601525"},{"key":"2025100306261502000_11.7.e007198.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2013.03.002"},{"key":"2025100306261502000_11.7.e007198.35","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830270141"},{"key":"2025100306261502000_11.7.e007198.36","doi-asserted-by":"crossref","first-page":"26841","DOI":"10.18632\/oncotarget.4754","article-title":"Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts Immunogenic Phagocytic removal","volume":"6","author":"Garg","year":"2015","journal-title":"Oncotarget [Internet]"},{"key":"2025100306261502000_11.7.e007198.37","doi-asserted-by":"publisher","DOI":"10.1038\/nature07750"},{"key":"2025100306261502000_11.7.e007198.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.009"},{"key":"2025100306261502000_11.7.e007198.39","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3386"},{"key":"2025100306261502000_11.7.e007198.40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0756"},{"key":"2025100306261502000_11.7.e007198.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34791-8","article-title":"Expanding cross-presenting Dendritic cells enhances Oncolytic Virotherapy and is critical for long-term anti-tumor immunity","volume":"13","author":"Svensson-Arvelund","year":"2022","journal-title":"Nature Communications"},{"key":"2025100306261502000_11.7.e007198.42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2116"},{"key":"2025100306261502000_11.7.e007198.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1800"},{"issue":"2 Pt 1","key":"2025100306261502000_11.7.e007198.44","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025100306261502000_11.7.e007198.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.11.042"},{"key":"2025100306261502000_11.7.e007198.46","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12308"},{"key":"2025100306261502000_11.7.e007198.47","doi-asserted-by":"crossref","unstructured":"Nadia C , Serena M , Carmela La M , et al . Phenotypical and functional analysis of memory and Effector human Cd8 T cells specific for Mycobacterial antigens. J Immunol 2006. doi:10.4049\/jimmunol.177.3.1780","DOI":"10.4049\/jimmunol.177.3.1780"},{"key":"2025100306261502000_11.7.e007198.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.003"},{"key":"2025100306261502000_11.7.e007198.49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2309"},{"key":"2025100306261502000_11.7.e007198.50","doi-asserted-by":"crossref","unstructured":"Morimoto K , Baba Y , Shinohara H , et al . Lrrk1 is critical in the regulation of B-cell responses and Carma1-dependent NF-\u039aB activation. Sci Rep 2016;6. doi:10.1038\/srep25738","DOI":"10.1038\/srep25738"},{"key":"2025100306261502000_11.7.e007198.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.02.023"},{"key":"2025100306261502000_11.7.e007198.52","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1796-7"},{"key":"2025100306261502000_11.7.e007198.53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.7096"},{"key":"2025100306261502000_11.7.e007198.54","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051782"},{"key":"2025100306261502000_11.7.e007198.55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.10.7157"},{"key":"2025100306261502000_11.7.e007198.56","first-page":"1456","article-title":"Enhancement of metastatic capacity of fibroblast-tumor cell interaction in mice","volume":"48","author":"Tanaka","year":"1988","journal-title":"Cancer Res"},{"key":"2025100306261502000_11.7.e007198.57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2431"},{"key":"2025100306261502000_11.7.e007198.58","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.17.8729-8736.2002"},{"key":"2025100306261502000_11.7.e007198.59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00429"},{"key":"2025100306261502000_11.7.e007198.60","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.84"},{"key":"2025100306261502000_11.7.e007198.61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2007.01090.x"},{"key":"2025100306261502000_11.7.e007198.62","doi-asserted-by":"publisher","DOI":"10.1177\/1753425915599242"},{"key":"2025100306261502000_11.7.e007198.63","doi-asserted-by":"publisher","DOI":"10.1038\/ni1223"},{"key":"2025100306261502000_11.7.e007198.64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805325105"},{"key":"2025100306261502000_11.7.e007198.65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.3.1983"},{"key":"2025100306261502000_11.7.e007198.66","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31827457bd"},{"key":"2025100306261502000_11.7.e007198.67","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory T cells populate tumors and can be Repurposed for tumor Immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat Commun"},{"key":"2025100306261502000_11.7.e007198.68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical Immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:26:26Z","timestamp":1759497986000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":68,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,24]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/jitc-2023-007198"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007198","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}